Companies listed on Euronext are indexed according to size, segments, sectors and per national market. It is not necessary to apply for inclusion in an index, just as a company cannot block its inclusion.

Amsterdam, Brussels, Lisbon, London and Paris - 14 December 2017 – Euronext today announced its approval by the French regulator, Autorité des Marchés Financiers (AMF), to provide Approved Publication Arrangement (APA) and Approved Reporting Mechanism (ARM) services to Investment Firms in Europe, from the introduction of MiFID II[1]on 3rd January 2018.

In July 2017, Euronext announced the enhancement of its Trade Publication and Transactions Reporting Services to meet the new obligations specified under MiFID II. The services will cover an expanded range of cash, commodity and derivatives markets under the scope of MiFID II, including non-Euronext products.

Euronext’s ARM service will connect to a range of European National Competent Authorities, including AMF, AFM, FCA, FSMA, CMVM and more.

Lee Hodgkinson, Head of Markets & Global Sales, said: “Regulatory reporting is an important part of MiFID II, providing security and transparency to European markets. This service, designed together with clients, will provide firms with a flexible solution to meet their obligations. We look forward to working with our clients on expanding our services going forwards.”

[1]MiFID II refers to Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on Markets in Financial Instruments; Regulation (EU) No 600/2014 of the European Parliament and of the Council of 15 May 2014 on Markets in Financial Instruments.

Amsterdam - 7 December: Euronext today announced the results of the quarterly review of the AEX®, AMX® and AScX® indices. The changes following the review will be effective from Monday 18 December 2017.

Results of the December 2017 Review

No changes in the composition of the AEX®, AMX® and AScX® following the quarterly review.

AEX®:

Inclusion of:

Exclusion of:

None

None

AMX®:

Inclusion of:

Exclusion of:

None

None

AScX®:

Inclusion of:

Exclusion of:

None

None

The compiler retains the right to change the published selection, for instance in case of a removal due to a take-over, till the publication of the final data after close of Wednesday 13 December 2017.

All events happening after that date will not lead to a replacement of the selected company that possibly needs to be removed from the final selection.

Review AEX family

The AEX family is reviewed quarterly in June, September and December. The full annual review is in March. The quarterly reviews serve to replace removed constituents and to facilitate inclusion of recently listed companies.

Lisbon – 7th December 2017 – Euronext today announced the results of the quarterly review for the PSI 20®. The changes due to the review will be effective from Monday 18 December, 2017.

Results of the Quarterly Review

PSI20®

No changes in the composition of the index.

Inclusion of:

Exclusion of:

None

None

The compiler retains the right to change the published selection, for instance in case of a removal due to a take-over, till the publication of the final data after close of Wednesday 13 December 2017.

All events happening after that date will not lead to a replacement of the selected company that possibly needs to be removed from the final selection.

Review PSI 20®

The PSI 20 is reviewed quarterly in June, September and December. The full annual review is in March.

The quarterly reviews serve to facilitate inclusion of recently listed companies and other eligible non constituents that rank 15th or better. Furthermore constituents whose ranking has become lower than 25th will be removed. Possibly eligible non constituents are added in order to maintain at least 18 constituents in the index.

Brussels, 7 December 2017 – Euronext today announced the results of the quarterly review of the BEL 20®, BEL Mid® and BEL Small®. The revised composition will be effective from Monday 18 December 2017.

BEL 20®

Inclusion of:

Exclusion of:

None

None

BEL Mid®

Inclusion of:

Exclusion of:

None

None

BEL Small®

Inclusion of:

Exclusion of:

None

None

The compiler retains the right to change the published selection, for instance in case of a removal due to a take-over, till the publication of the final data after close of Wednesday 13 December 2017. All events happening after that date will not lead to a replacement of the selected company that possibly needs to be removed from the final selection.

Review BEL 20®, BEL Mid® and BEL Small®

The BEL family is reviewed quarterly (March, June, September, December). The full annual review of the BEL 20® is in March. The June, September and December reviews of the BEL 20® serve to facilitate inclusion of recently listed companies and other eligible non constituents that rank 10th or better. Furthermore constituents whose ranking has become lower than 30th will be removed. Possibly, eligible non constituents are added if there are less than 20 constituents in the index.

Paris – 7th December 2017 – Euronext today announced the results of the quarterly reweighting of the CAC family indices. The changes following the review will be effective from Monday 18 December 2017.

Paris – 6 December 2017 – Advicenne, a pharmaceutical SME from the south of France at advanced stages of development, today celebrated its first day of trading on Euronext Paris. Funds raised through listing will help the company pursue clinical development of its leading product in Europe and the United States, and finance commercial growth in Europe.

Founded in Nîmes in 2007 by Dr Luc-André Granier, MD, and Caroline Roussel-Petit, respectively Chairman & CEO and Director of Operations, Advicenne develops therapeutic products for children and adults suffering from rare renal and neurological diseases. From the start, the company has been backed by leading venture capital investors including InnoBio (Bpifrance), IXO Private Equity, IRDI Soridec Gestion, Cemag Invest and MI Care, as well as private investors.

Advicenne (ticker code ADVIC) was listed through the admission to trading on 6 December 2017 of 8,002,696 shares making up the company’s equity, including 2,007,718 new shares (after partial exercise of the extension clause and before exercise of the overallotment option), raising a total of €27 million euros, and may rise to €28.2 million euros in case of full-exercise of the over-allotment option.

The offering price was set at €14,03 per share and market capitalisation was around €112 million on the day of listing.

At the listing ceremony, the company’s co-founder, Chairman & CEO Dr. Luc-André Granier, said: “We are delighted to have completed our initial public offering on Euronext Paris, and to welcome new investors alongside our historical shareholders, who have confirmed their ongoing support for our team and our work. We would like to thank each and every one, both individuals and institutions, for placing their trust in Advicenne. This IPO represents a milestone in our strategy, and will enable us to pursue the clinical development of our lead product in both Europe and the United States, and lay the groundwork for its planned commercialisation in Europe in 2020.”

Amsterdam, Brussels, Lisbon, London and Paris – 05 December 2017 – Euronext, the leading pan-European exchange in the Eurozone, today announced trading volumes for November 2017.

Cash Trading
In November 2017, the average daily transaction value on the Euronext cash order book stood at €8,141 million, up +11.0% compared to November 2016 and up +13.5% from the previous month. The average daily transaction value on ETFs was €481 million, down -22.1% compared to November 2016 and up +21.6% from the previous month. Euronext’s ETF offering slightly decreased this month to 828 listings at the end of November, compared to 831 at the end of the previous month. As a reminder, 790 ETFs were listed on Euronext markets at the end of 2016.

Derivatives trading
In November 2017, the overall average daily volume on derivatives reached 629,767 contracts, up +15.9% compared to November 2016 and up +26.5% compared to the previous month. In details,

the average daily volume on equity index derivatives reached 219,503 contracts, down -7.0% compared to November 2016 and +14.5% from the previous month,

the average daily volume on individual equity derivatives reached 350,175 contracts in November 2017, up +37.0% compared to November 2016 and +32.1% from the previous month,

the average daily volume on commodities derivatives reached 60,089 contracts, up +16.6% compared to November 2016 and +46.9% from the previous month.

On a year-to-date basis, at end of November 2017, the overall average daily volume on Euronext derivatives stands at 551,326 contracts (+11.9% compared to end of November 2016) and the open interest was up at 19,727,262 contracts (+17.8% compared to end of November 2016).

FX spot trading
The average daily volume on the spot foreign exchange market of FastMatch, of which Euronext owns 90% of the capital since August 2017, stood at $17,777 million, up +3.9% compared to November 2016 and down -1.4% from the previous month.

Listing
In November 2017, Euronext had one technical listing, Reinet Investments on Euronext Amsterdam. In addition, €3.3 billion were raised on Euronext in corporate bonds and €2.0 billion of follow-on equity, including Eurofins Scientific €299m private placement and Erytech Pharma €107m capital increase.

Enhancement of Euronext’s post-Brexit strategic positioning as an open and international venue

Closing expected in Q1 2018, subject to regulatory approvals

Transaction to deliver significant value creation:

Strong core growth for ISE complemented by additional growth opportunities for the combined group and €6m of expected pre-tax run-rate cost synergies

Strengthening of Euronext’s revenue profile with the addition of leading global franchises in debt, funds and ETF listings

Expected return on capital employed above cost of capital within year three, in line with Euronext disciplined M&A approach, and EPS accretive from year one

Stéphane Boujnah, Chief Executive Officer and Chairman of the Managing Board of Euronext said: “The Irish Stock Exchange joining Euronext represents a major milestone in the expansion of Euronext’s federal model since its IPO. ISE brings to Euronext leading global positions in debt, funds and ETF listings markets. As part of Euronext, ISE’s growth initiatives will be reinforced with Euronext’s full support. We are delighted to welcome Deirdre Somers and her team to Euronext. In addition to strengthening revenue profile and cost synergies, ISE is ideally positioned to benefit from market opportunities in a post-Brexit environment. Within this environment, our unique federal model clearly demonstrates its added value through a single cross-country liquidity pool, a single state-of-the-art proprietary technology, a single rule book and a complete and diversified set of services, while maintaining strong local input within our balanced federal governance. This transaction demonstrates the strength of the Euronext “united in diversity” federal model.”

Deirdre Somers, Chief Executive Officer of ISE commented: ”This is a landmark day in the 224-year history of ISE and a great day for our customers and our people. This transaction recognises the significant value and leading market position that has been built by the ISE. More importantly, we believe that Euronext is the perfect partner to enable us to achieve our growth ambitions. Euronext is hugely complementary to the ISE, bringing valuable expertise, financial strength, global relationships and technological capability as well as a global brand. These will enable our business to build further on its track record of international achievement and capitalise on new market and product opportunities emerging in Europe.”

Euronext expands its federal model with the acquisition of the Irish Stock Exchange

A strategic venue to join Euronext’s federal model

Headquartered in Dublin, ISE is Ireland’s incumbent stock exchange operator and a global leader in the listing of debt and funds securities. ISE is the first pool of liquidity for Irish equities (51 listed companies, c. €122bn total domestic equity market capitalisation[3]), the first debt listing venue globally (30,000+ securities and listings1 from 90 countries) and the first fund listing venue globally (5,242 Investment Funds Securities and 227 ETFs1).

ISE generated revenue of €29.4m, EBITDA of €9.6m and a net income of €8.0m in 2016. For the first 9 months of 2017, ISE generated €24.2m of revenue, up +13.3% compared to the same period in 2016, and an EBITDA of €8.5m, up +22.4% compared to the same period in 2016.

The combined group pro forma 9 months of 2017 revenue would amount to €416.9m and an EBITDA of €227.7m before synergies.

ISE to join Euronext’s federal model for further growth opportunities and increased efficiency

The transaction brings together two highly complementary businesses with significant growth opportunities and expands Euronext’s federal model to a new attractive European country. It creates a leading global player in debt and fund listings, combining the listing expertise of ISE with the traded markets expertise of Euronext.

Euronext will benefit from ISE’s leading global positions in debt and fund listings as well as its unique product and listing expertise. The acquisition will also enhance Euronext’s growth outlook thanks to ISE’s embedded core businesses’ growth, complemented by the additional strategic growth plans for ISE, which will be reinforced with the full support of Euronext.

Ideal positioning of ISE in a dynamic environment, to take advantage of post-Brexit opportunities

The acquisition of ISE by Euronext, combined with Ireland’s very competitive economic environment, will further strengthen Ireland’s position as a strong European anchor to take advantage of Brexit opportunities. This transaction will also develop the Irish capital markets ecosystem within a European context and as part of Euronext’s core mission to power the real economy.

ISE is at the centre of Ireland’s highly competitive financial ecosystem. The country provides a recognized finance-friendly environment, with a highly educated workforce, and a business-oriented mind-set, as well as an attractive economy within the Eurozone, with forecast GDP growth of c.3.8%[4] 2017e-18e. Ireland is in a strong position to seize opportunities arising from Brexit since it is both close to the UK business culture and strongly rooted inside the Eurozone.

Dublin will have a strong group-wide position within Euronext’s highly inclusive federal governance structure, notably as the global centre of excellence for all Euronext’s group-wide activities in the listing of debt, funds and ETF securities.

ISE will then benefit from a strong European anchor to support and develop the Irish listed companies’ ecosystem within a European context and as part of Euronext’s core mission to power the real economy.

Padraic O’Connor, Chairman (Non-Executive) of ISE will be proposed as a new member of Euronext’s Supervisory Board to the next Annual General Meeting of Euronext.

In addition, ISE’s regulator, the Central Bank of Ireland, is expected to join Euronext’s College of Regulators.

A stronger future for ISE within the Euronext federal model

Euronext will provide ISE with its traded markets expertise, large customer base, state-of-the-art proprietary technology and widespread distribution channels, as well as a full suite of pre and post listing services to ISE equity issuers.

The combination will increase liquidity and efficiency for issuers, members and listing customers through the integration of ISE members to Euronext’s trading platform. ISE’s additional incremental growth opportunities include:

Leverage the unique complementarity of the Irish market to the UK to deliver Brexit solutions

Combine ISE’s global position in debt listing with Euronext Synapse as a catalyst for future fixed income innovation

Increased efficiency thanks to integration of ISE within Euronext

The transaction is financially compelling for Euronext’s shareholders with recurring EPS accretion in the first year and return on capital employed above Euronext’s cost of capital within year three.

The integration of ISE within Euronext is expected to generate run-rate pre-tax operating cost synergies of €6m per annum, to be fully delivered in 2020, primarily driven by i/ the migration to OptiqTM, Euronext’s new state-of-the-art proprietary trading platform, ii/ the aggregation of a Pan-European offering on market data by migrating ISE’s current offering onto Euronext’s platform and iii/ ISE benefiting from using Euronext’s support functions.

As part of the integration, total costs of c.€9m will be incurred in the first years of implementation, with full integration expected by 2020.

Continued financial discipline while optimising balance sheet structure of Euronext

This acquisition is part of Euronext’s strategy to actively leverage its balance sheet, while retaining financial flexibility, to capture value accretive opportunities and accelerate growth and strengthen its revenue profile.

Euronext is to pay for 100 % of ISE’s shares €137 million of enterprise value on a debt free, cash free basis, and excluding existing regulatory capital requirements (estimated at €21.8m). The transaction will be fully funded by debt.

As a reminder, as of 30 September 2017, Euronext had cash and cash equivalents of €140.6m, and €164.7m of outstanding long-term debt and strong liquidity through an undrawn Revolving Credit Facility of €250m.

Transaction timetable and requirements

ISE is currently owned by five Irish financial institutions, J&E Davy, Goodbody Stockbrokers, Investec Capital & Investments, Cantor Fitzgerald and Campbell O’Connor that have all committed to sell their shares.

The transaction is subject to regulatory approvals and is expected to close in Q1 2018.

Index components[1] are reviewed and updated twice a year, in June and in December. Full details are shown in the appended tables and on Vigeo Eiris website. Decisions made today will take effect in the trading session starting Thursday, December 1st, 2017.

This latest update of this index range includes 30 new component companies. A total of 32 companies were removed from the range.

Methodology

New component stocks are those awarded the highest overall scores by the Vigeo Eiris agency, using the Equitics® methodology. These include top ratings for companies' ability to master risks related to social responsibility and deploy strong commitments in support of sustainable development. Vigeo's assessment model rates each company on nearly 330 indicators. No sectors are excluded per se.

However following a decision by the Indices Committee, companies that are the subject of controversy on critical issues involving social responsibility and that do not supply comprehensive public information on corrective measures taken or discussions they may have entered into with stakeholders regarding such controversies, are excluded.

Companies’ weighting in the index, calculated by Euronext, is correlated with the rating assigned by the Vigeo Eiris agency. This represents an alternative approach to traditional methods based on float. It allows for positive discrimination in favour of those listed companies—most of which operate internationally—that are the most actively engaged in promoting compliance with universal public standards, particularly in the field of human rights, decent employment practices, environmental protection, governance, business ethics and contributions to economic development and social progress in relevant areas.

Vigeo Eiris is a global provider of environmental, social and governance (ESG) research to investors and public and private corporates. The agency evaluates the level of integration of sustainability factors in the strategy and the operations of organizations, and undertakes a risk assessment to assist investors and companies in decision-making.Vigeo Eiris offers two types of services through separate business units:

Vigeo Eiris enterprise asseses organizations of all sizes, listed and not listed companies in order to support them in the integration of ESG criteria into their business functions and strategic operations.

Vigeo Eiris methodologies and rating services adhere to the strictest quality standards and have been certified to the independent ARISTA® standard. Vigeo Eiris is CBI (Climate Bond Initiative) Verifier.

Vigeo Eiris is represented in Paris, London, Boston, Brussels, Casablanca, Hong Kong, Milan, Montreal, Rabat, Santiago, Stockholm and Tokyo. The team is composed of more than 200 experts of 28 nationalities with diversified and complementary skills. Vigeo Eiris has developed the Vigeo Eiris Global Network made of 7 research providers (Australia, Brazil, Germany, Israel, Japan, Spain and Mexico).For more information:www.vigeo-eiris.com

About Euronext
Euronext is the leading pan-European exchange in the Eurozone with nearly 1,300 listed issuers worth close to €3.6 trillion in market capitalisation as of end September 2017, an unmatched blue chip franchise consisting of 24 issuers in the Morningstar® Eurozone 50 Index℠ and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM (formerly known as Alternext) and Euronext AccessTM (formerly known as the Free Market). For the latest news, find us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).Disclaimer
This press release is for information purpose only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

[1] See appendix for a complete list of Euronext-Vigeo Eiris index components. The next revision will take place in June 2018.

New York, 21 November 2017 – FastMatch, Inc., the fastest growing FX spot market operator, which has operated as a Euronext company since August 2017, announced today that individuals may now purchase FX Tape data from its website at a cost of €40 a month, using their credit cards.

FX Tape is a new and innovative market data product that improves post-trade transparency in FX markets and allows market participants to monetize their trading data. FX Tape will also serve as a central reference point for spot FX transacted prices, helping individuals and companies to benchmark their FX rates. Typically such trading data costs thousands of euros a month and requires special programming in order to receive it, so the average consumer cannot access the data.

“FastMatch is bringing transparency in spot FX to anyone with a credit card”, said Dmitri Galinov, CEO of FastMatch, Inc. “Now, for a small monthly fee, individuals and companies can view the latest FX rates transacted on interbank markets. This information empowers them to demand better FX rates from vendors.”

The FX Tape is open to all contributors under an open access model with a percentage of the net revenue generated by FX Tape shared with contributors, according to the volume contributed.

At opening, based on a reference price of € 17.29 per share, the total market capitalisation of Reinet Investments was approximately € 3,38 billion.

Reinet Investments, which was created in 2008, allows its shareholders to participate indirectly in the portfolio of assets held by its wholly-owned subsidiary Reinet Fund S.C.A., F.I.S. (“Reinet Fund”), a closed-ended specialised investment fund established in Luxembourg.

The investment strategy of Reinet Fund is built on the principle of taking a long term view of investment opportunities. Its goal is to invest its assets for long-term growth, directly or through selected partners, in a wide range of underlying assets, seeking investment opportunities where it can add value.

Wilhem van Zyl, Chief Executive Officer at Reinet Investments, said: “It is a great pleasure to be in Amsterdam today to initiate and celebrate the listing of Reinet Investments on Euronext Amsterdam. Our goal is to improve the liquidity in the market of our shares. By this listing we are granting our investors access to another market trading platform which should make it easier to trade our shares. As Euronext Amsterdam is broadly recognised for its diverse and international investor base we are confident that this new listing will provide us with increased access to European-based investors with the resulting potential to broaden our shareholder base.”

Reinet Investments celebrated their listing by the sounding the gong, which denotes the opening of trading of Reinet Investments on Euronext Amsterdam.

About Reinet Investments S.C.A.
Reinet Investments S.C.A. is a securitisation vehicle incorporated as a société en commandite par actions (partnership limited by shares). Reinet Investments S.C.A. ordinary shares are listed and traded on the Luxembourg Stock Exchange, and as of today the Company's ordinary shares are listed on Euronext Amsterdam and the depository receipts issued by Reinet Securities SA in respect of Reinet Investments S.C.A. ordinary shares are traded as a secondary listing on the Johannesburg Stock Exchange. It is regulated by the Commission de Surveillance du Secteur Financier and its sole purpose is to allow its shareholders to participate indirectly in the portfolio of assets held by its wholly-owned subsidiary Reinet Fund S.C.A., F.I.S., a specialised investment fund, or SIF, established as a partnership limited by shares (société en commandite par actions) under the laws of Luxembourg.
Further information on Reinet may be found at www.reinet.com.

Signing of a 10-year agreement with LCH SA for financial and commodities derivatives clearing, and the swap of a 2.3% minority stake in LCH Group with a 11.1% stake with a pre-emption right[3] in LCH SA (to be closed in the next few months)

Stéphane Boujnah, CEO and Chairman of the Managing Board of Euronext NV., said:

“Euronext’s results for the third quarter of 2017 were driven by the improvement of volume in a stabilised macro environment and by the first contributions of our new acquisitions. We ensured a +13.3% growth in EBITDA this quarter, while we pursued major projects such as MiFID II and Optiq®. This quarter was marked by the deployment of our Agility for Growth strategic plan, through the acquisition of iBabs in July, and by the closing of the acquisition of FastMatch in August. Another major milestone was met in August when we secured the renewal of a 10-year agreement for derivatives clearing with LCH SA, as well as a 11.1% stake and a pre-emption right in this company, ensuring a long-term and improved value proposition for our customers and investors.”

Amsterdam, Brussels, Lisbon, London and Paris – 3 November 2017 – Euronext, the leading pan-European exchange in the Eurozone, today announced trading volumes for October 2017.

Cash Trading

In October 2017, the average daily transaction value on the Euronext cash order book stood at €7,172 million, up +13.3% compared to October 2016 and down -1.7% from the previous month.

The average daily transaction value on ETFs was €396 million, down -6.1% compared to October 2016 and down -8.4% from the previous month. Euronext’s ETF offering increased this month to 831 listings at the end of October 2017 compared to 790 end of 2016.

Derivatives trading

In October 2017, the overall average daily volume on derivatives reached 497,684 contracts, up +8.6% compared to October 2016 and stable (-0.8%) compared to the previous month. In details,

the average daily volume on equity index derivatives reached 191,769 contracts, down -5.2% compared to October 2016 and -5.2% from the previous month,

the average daily volume on individual equity derivatives reached 265,006 contracts, up +27.9% compared to October 2016 and +3.3% from the previous month,

the average daily volume on commodities derivatives reached 40,910 contracts, down -16.1% compared to October 2016 and -4.1% from the previous month.

On a year-to-date basis, at end of October 2017, the overall average daily volume on Euronext derivatives stands at 543,262 contracts (+11.5% compared to end of October 2016) and the open interest was up at 18,302,547 contracts (+15.3% compared to end of October 2016).

FX spot trading

The average daily volume on the spot foreign exchange market of FastMatch, of which Euronext owns 90% of the capital since August 2017, stood at $18,030 million, up +33.0% compared to October 2016 and down -13.6% from the previous month.

Listing

In October 2017, Euronext had four listings on its Paris markets –SMCP, Biom’ Up, Adeunis and Theranexus –that altogether raised €607 million. In addition, €7.1 billion were raised on Euronext in corporate bonds and €3.8 billion of follow-on equity, including Total for €1.1 billion and Air France-KLM for €1.0 billion.

New York, 2 November 2017 – FastMatch, Inc., the fastest growing FX spot market operator, which has operated as a Euronext company since August 2017, announced today that it has opened a sales office in Greenwich, CT.

High-quality level of service is one of the differentiating features contributing to FastMatch’s growth and success. In order to maintain this level of service, it is important for FastMatch to be located near its major customers. The opening of the Greenwich, CT office in addition to FastMatch’s offices in New York, London and Moscow is an important step in expanding its touch points with major customers.

“The FX market has seen a significant rise in the use of electronic trading tools by the buy side”, said Dmitri Galinov, CEO of FastMatch. “We are excited to be closer to our hedge fund clients and help them with their transition to new trading methods in FX.”

About FastMatch
FastMatch is a new Electronic Communication Network for foreign exchange trading. FastMatch strives to offer its customers access to large pools of diversified liquidity at unparalleled speed with complete transparency in the optimal location. Its award-winning technology gives FastMatch an important speed advantage and has the capability of handling thousands of clients simultaneously. Clients include retail brokers, institutions, banks, hedge funds, and proprietary trading firms. FastMatch is a company of Euronext, the leading pan-European exchange in the Eurozone.

Amsterdam, Brussels, Lisbon, London and Paris – 1 November 2017 – Euronext, the leading pan-European exchange in the Eurozone, announces the signing of the renewal of its agreement with LCH SA on the continued provision of derivatives and commodities clearing services for a period of 10 years. This follows the announcement of 8 August 2017.

The new long-term agreement covers the clearing of financial and commodity derivatives for a period of 10 years. It provides continuity of clearing services for members, saving the cost and disruption associated with a migration at a time where client bandwidth is stretched due to MiFID II implementation and Brexit planning. Euronext and LCH SA will work together to develop new products for the benefit of clearing members and market participants, and to focus on providing a lower cost service for members. In addition the agreement provides a comparable revenue sharing mechanism delivering a continued clearing income stream for Euronext.

Euronext entered into definitive agreements to swap its current 2.3% stake in LCH Group for an 11.1% stake in LCH SA. This transaction is subject to regulatory review and is expected to close in the next few months. Euronext will recognise a net capital gain following the share swap of around €24m. This transaction will strengthen the long-standing relationship between Euronext and LCH SA, and cement the strategic future of LCH SA.

Euronext will remain on the Board of LCH SA following completion of the share swap. Euronext will also nominate one representative to LCH SA Audit Committee and will continue to be represented at LCH SA Risk Committee. A new Consultative Committee dedicated to Euronext derivatives business will be created.

Euronext will have certain minority protection rights connected with its new shareholding in LCH SA, including a pre-emption right in circumstances where LCH Group decides to sell more than 50% of the shares of LCH SA. The pre-emption right involves a right of first offer and subject to certain conditions, a matching right. In addition, LCH Group has a pre-emption right over a transfer of shares by Euronext and the ability to buy back Euronext's shares in certain circumstances where the derivatives agreement is terminated.

About LCH
LCH is a group of leading multi-asset clearing houses that provides proven risk management capabilities across a range of asset classes. As demand for robust clearing services continues to grow, LCH is committed to maintaining the highest standards of risk management across all our services.
As the markets’ partner, LCH operates an open access model, offering a choice of execution venues, delivering unprecedented choice and efficiencies to the marketplace.
LCH operates clearing houses around the world, with clearing houses incorporated in the UK, France and the United States with additional offices in the Asia Pacific region. It offers clearing services across asset classes including OTC and listed rates; CDS and FX; fixed income; commodities; cash equities and equity derivatives.
LCH is majority owned by London Stock Exchange Group (LSE.L), an international markets infrastructure business that sits at the heart of the world's financial community.
Further information on LCH can be found at www.lch.com

Paris – 30 October 2017– Theranexus, a French biotech company that develops drugs for the treatment of central nervous system disorders, celebrated today its listing on Euronext Growth (ticker code: ALTHX). Theranexus was part of the first TechShare class of 2015, and is the third company in the programme to go public, joining a community of over 330 tech companies listed on Euronext.

Founded in 2013 by researchers at the CEA (French Alternative Energies and Atomic Energy Commission), Theranexus is a biopharmaceutical company that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders – including narcolepsy, Parkinson’s disease, Alzheimer’s disease and neuropathic pain. Theranexus has successfully identified the key role that non-neuronal cells (or “glial cells”) play in how neurons respond to CNS drugs. The company designs and develops ground-breaking drugs that act simultaneously on both cell types within the brain.

Theranexus’ unique patented technology is designed to increase the efficacy of previously approved and marketed CNS drugs by combining them with glial cell modulators. By combining and repurposing drugs in this way, the company can substantially cut development time and cost – thereby boosting its drug candidates’ chances of making it to the market. The proprietary, scalable Theranexus platform is able to generate a variety of high value-added proprietary drugs for several therapeutic indications. Theranexus is currently developing three candidate drugs for four indications. THN102, the most advanced one, is already in phase II clinical trials.

Theranexus was listed through the admission to trading on 30 October 2017. The company has a total of 3,065,390 shares, including 1,262,194 new shares issued as part of a Global Offering[1], raised €19.6 million after full exercise of the extension clause, which may rise to €21.0 million if the over-allotment option is fully exercised.

The Offering price was set at €15.50 per share. The company’s total market capitalisation the day of its IPO was €47.5 million.

Franck Mouthon, Theranexus Co-founder, Chairman and CEO, said: “We would like to thank the institutional investors and individuals who believe in our company and took part in our IPO. And we would especially like to thank our long-standing shareholders who have renewed their support, giving us their full backing for our ambitious growth strategy. The funds we raised will let us continue to proactively develop and leverage our platform and portfolio of drug candidates.”

TechShare is a pan-European programme launched by Euronext in 2015 to help leaders of tech SMEs to better understand financial markets and how they work. Spanning individual coaching sessions, talks and workshops, the ten-month course enabled Theranexus to weigh the benefits of going public as a way to finance its growth strategy.

[1]The Global Offering is a public offering that consists of an open-price offering and a private placement among institutional investors in France and abroad.

Paris – 20 October 2017 – SMCP, the parent company of French apparel and accessories brands Sandro, Maje and Claudie Pierlot, today celebrated its first day of trading in Compartment A of Euronext Paris. CEO Daniel Lalonde rang the bell that opens European markets, accompanied by Evelyne Chétrite and Judith Milgrom, the founders and artistic directors of the Sandro and Maje brands, and Ilan Chétrite, founder and artistic director of the Sandro men’s label.

SMCP is an international player in the global apparel and accessories market consisting of three strong Paris-designed brands: Sandro, Maje and Claudie Pierlot, whose desirability has grown significantly around the world in the recent years. They share the mission of spreading Parisian chic across the world.

SMCP’s business model that blends the codes of luxury and fast fashion has allowed the group to deliver powerful results. With net sales reaching €786 million in 2016, averaging a 27% increase per year since 2010, SMCP has recorded strong growth in the past few years and excellent results in 2016. It is now present in 36 countries through more than 1,200 retail outlets.

SMCP’s initial public offering is the fifth listing in Compartment A of Euronext Paris since January 2017.

SMCP (ticker code SMCP) was listed on 20 October 2017 through the admission to trading of 73,170,023 SMCP shares. In the context of the Global Offering1, 24,612,687 shares have been issued, including 5,772,728 new shares and 18,839,959 existing shares sold by European TopSoho Sàrl, the US investment fund KKR, and company executives, before any potential exercise of the over-allotment option.

The offering price was set at €22 per share. The total amount of the offer represents €541 million.

At the listing ceremony, CEO Daniel Lalonde said: “We are very pleased with the success of this new IPO. This is an important milestone that opens the first of many new chapters in SMCP’s tremendous growth story. The very positive response we received reflects the desirability of our brands as well as investor confidence in SMCP's business model and growth prospects.”

1 The Global Offering was made up of a Public Offering that included an Open Price Offer (OPO) in France and a Global Placement in France and other countries, primarily with institutional investors.

About SMCP
SMCP is a global player in the apparel and accessories market with three distinct contemporary Parisian fashion brands, Sandro, Maje and Claudie Pierlot. As of end of June 2017, SMCP brands are present in more than 1,200 points of sale in 36 countries. Evelyne Chetrite and Judith Milgrom founded Sandro and Maje in Paris, in 1984 and 1998 respectively, and continue to provide creative direction for the brands. Claudie Pierlot was founded in 1984 by Madame Claudie Pierlot, and acquired by SMCP in 2009.www.smcp.com

Amsterdam, Brussels, Lisbon, London and Paris – 20 October 2017 – Euronext today announced the 2018 trading days for its markets in Amsterdam, Brussels, Lisbon, London and Paris.

Euronext’s Cash and Derivatives markets will be open Monday to Friday throughout 2018 except on the following days:

Monday 1 January 2018 (New Year’s Day)

Friday 30 March 2018 (Good Friday)

Monday 2 April 2018 (Easter Monday)

Tuesday 1 May 2018 (Labour Day)

Tuesday 25 December 2018 (Christmas Day)

Wednesday 26 December 2018 (Boxing Day)

On Monday 24 December 2018 (Christmas Eve) and on Monday 31 December 2018 (New Year’s Eve), trading on the Cash markets will be half day trading, with all instruments closing by 14:05 CET. Contracts on the Derivatives markets will close at various times, commencing at 13:55 CET.

Paris – 16 October 2017 – Adeunis, a French tech SME specialised in wireless connected objects, celebrated its listing on the Euronext Growth Paris market today during a ceremony at the Paris stock exchange attended by management, contributors and advisers.

Founded in 2000 in the French Alps (Crolles), Adeunis manufactures and markets connected sensors and ready-to-use wireless solutions dedicated to the Internet of Things (IoT) and machine-to-machine communication that ensure the secure transmission of data. The company financed its own growth until 2011, when it was joined by investors including A Plus Finance, Capital Export and Tempocap. Its expertise has driven expansion in Europe and the United States, generating sales of over €9 million in 2016.

Adeunis (ticker code ALARF) was listed through the admission to trading on 16 October 2017 of 2,182,960 shares, including 736,757 new shares issued as part of a Global Offering[1].

The offering price was set at €10.11 per share. Market capitalisation was around €22million on the day of listing, and the IPO raised a total of €7.4 million.

At the listing ceremony, Adeunis CEO Pascal Saguin stated: “We would like to extend warm thanks to our institutional and individual investors for their trust and confidence. We also want to thank our longstanding shareholders who have stood by us once again and who share our strategy for bold growth. Funds raised by listing will be used to accelerate our deployment across Europe and the United States, and step up growth on markets focusing on industrial IoT and professional audio solutions.”

[1] The Global Offering was made up of a Public Offering that included an Open Price Offer (OPO) in France and a Global Placement in France and other countries, primarily with institutional investors.

About Adeunis
Founded in 2000, Adeunis designs, manufactures and commercialises sensors and wireless solutions that enhance operational performance in today’s connected world. Specialised in securely capturing and transmitting data, its five million solutions meet the specific needs of sectors as varied as building management, process optimisation, sports and services. Adeunis’ targeted technology solutions and industrial-scale capacity have won over clients such as Areva, EDF, Enedis, Legrand, the French Professional Football League, OCEA Smart Building, SNCF, Suez and Veolia Environnement.
With offices in France and the United States, and an international distribution network, Adeunis reported sales of over €9 million in 2016. For more information, visit www.adeunis.com

€38.1 million raised; market capitalisation approximately €113.4 million

Paris – 13 October 2017 – Biom’Up, a specialist in hemostatic products used in surgery, listed today in Compartment C of Euronext Paris, joining the community of over 330 small and mid-sized tech companies – including more than 80 operating in life sciences – on Euronext’s pan-European markets.

Thanks to a world-renowned medical team and their scientific expertise in the field of biopolymers, Biom’Up has developed HEMOBLAST™ Bellows, a world-class hemostatic product that aims to control bleeding during surgical operations (e.g., spine, heart, orthopedic or general surgeries). Bleeding leads to complications during surgery and lengthens the surgical procedure. Therefore hemostatic products are crucial in surgical operations that present a significant risk of bleeding. Today these products represent a global growth market estimated at 2 billion dollars. The US and European markets already established (e.g., spine and cardiovascular surgeries) represent an opportunity of 1.2 billion dollars.

HEMOBLAST™ Bellows obtained the CE Mark in December 2016, and the PMA (Pre-Market Approval) application was submitted to the FDA (Food & Drug Administration) in July 2017 with a view to obtaining marketing approval in the United States in mid-2018.

Biom’Up (ticker code BUP) was listed through the admission to trading on 13 October 2017 of 10,802,907 shares including 3,631,579 new shares issued as part of a Global Offering[1] including the full exercise of the extension option and excluding the potential exercise of the over-allotment option.

The offering price was set at €10.5 per share. Market capitalisation was around €113.4 million on the day of listing, and the IPO raised a total of €38.1 million.

At the listing ceremony, Etienne Binant, Chief Executive Officer of Biom’Up, said: “I am very pleased to announce today the success of our IPO on the regulated market of Euronext in Paris. I welcome the new French, European and American shareholders, and thank them for their trust. This operation was made possible by the empowerment and the financial investment of the management team (Bill Spotnitz, João-Paulo Alves and Jan Ohrstrom), as well as the support of the historical shareholders. We are now in the most favourable conditions to deploy our range of hemostatic products – especially HEMOBLAST™ Bellows – in Europe and North America. We will maintain our R&D investments and conduct new clinical studies to gain access to new surgical indications for the benefit of patients and clinicians.”

[1]The Global Offering was made up of a Public Offering that included an Open Price Offer (OPO) in France and a Global Placement in France and other countries, primarily with institutional investors.

About Biom’Up
Founded in 2005 and based in the Lyon suburb of Saint-Priest (France), Biom’Up designs hemostatic products based on patented biopolymers that aim to simplify surgical procedures in numerous specialties (spine, cardiothoracic, general, orthopedic, plastic) and give patients a better quality of life. Its flagship product, HEMOBLAST™ Bellows, is a unique hemostatic solution, ready to use (no preparation time needed, no need to mix, no heat required), usable once or several times during the surgery. Developed by a world-renowned scientific team, HEMOBLAST™ Bellows has obtained positive results for all the primary and secondary endpoints of Phase III of its pivotal study involving 412 patients in the United States. HEMOBLAST™ Bellows obtained its CE Mark in December 2016, and its PMA (Pre-Market Approval) application was submitted to the FDA (Food & Drug Administration) in July 2017 with a view to obtaining marketing approval in the United States in mid-2018. Since its creation, Biom’Up has benefited from the support of prominent European investors such as Bpifrance, Innobio, GIMV, Lundbeckfond, Mérieu XParticipation, SHAM and ACG, as well as all the Company’s managers, who have invested €2 million in equity.

About EuronextEuronext is the leading pan-European exchange in the Eurozone with nearly 1,300 listed issuers worth close to €3.6 trillion in market capitalisation as of end December 2017, an unmatched blue chip franchise consisting of 24 issuers in the Morningstar® Eurozone 50 Index℠ and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM (formerly known as Alternext) and Euronext AccessTM (formerly known as the Free Market). For the latest news, find us on Twitter (www.twitter.com/euronext) and LinkedIn (www.linkedin.com/company/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.